SCHEMBL4873559

SCHEMBL4873559

CS(=O)(=O)c1ccc(Oc2cc(Cl)ccc2N)c(Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.55
PTGS1 P23219 3/20 0.55
CYP2C9 P11712 1/20 0.47
PTGDR2 Q9Y5Y4 2/20 0.46
HPGD P15428 2/20 0.44
ALDH1A1 P00352 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
G6PD P11413 1/20 0.43
IDE P14735 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395063 0.86 PTGS2 (0.44) PTGS2PTGS1G6PDIDECA12
SCHEMBL2393406 0.86 PTGDR2 (0.49) PTGS2PTGS1CYP2C9PTGDR2HPGD
SCHEMBL3936441 0.84 PTGS2 (0.53) PTGS2PTGS1CYP2C9PTGDR2HPGD
SCHEMBL1333614 0.84 PTGS2 (0.53) PTGS2PTGS1PTGDR2ALDH1A1LMNA
SCHEMBL1331564 0.83 PTGS2 (0.52) PTGS2PTGS1CYP2C9PTGDR2HPGD
SCHEMBL1650304 0.83 PTGS2 (0.52) PTGS2PTGS1CYP2C9PTGDR2HPGD
SCHEMBL4965689 0.81 TTR (0.58) CYP2C9HPGDALDH1A1POLBGAA
SCHEMBL1650119 0.80 PTGS2 (0.47) PTGS2PTGS1CYP2C9PTGDR2HPGD
SCHEMBL1653539 0.80 PTGDR2 (0.49) PTGS2PTGS1CYP2C9PTGDR2HPGD
SCHEMBL1651593 0.80 PTGS2 (0.49) PTGS2PTGS1CYP2C9PTGDR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765768-B1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2013-11-06 EP disclosed
CN-102557971-A Substituted acids for the treatment of respiratory diseases ASTRAZENECA AB 2012-07-11 CN disclosed
CN-101014564-B Substituted acids for the treatment of respiratory diseases ASTRAZENECA AB 2012-05-09 CN disclosed
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases ASTRAZENECA AB (SE) 2008-05-15 US disclosed
EP-1765768-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES AstraZeneca AB (SE) 2007-03-28 EP disclosed
WO-2006005909-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases HRH2, HRH1, HRH4 PTGS2 376/4885PTGS1 231/4885CYP2C9 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.